Breast Cancer Clinical Trials

Showing 1721-1740 of 4,817 trials

GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

NCT05239663

The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.

Sun Yat-sen University76 participantsStarted Feb 2022

Guangzhou, Guangdong, China

Active Not RecruitingPhase 2

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

NCT06531447

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Breast Cancer

The National Center of Oncology, Azerbaijan200 participantsStarted May 2014

Baku, Azerbaijan

TERMINATEDPhase 3

GM1 Prophylaxis for WBRT Related Cognitive Dysfunction

NCT04395339

To evaluate the efficacy and safety of GM1 for preventing cognitive impairment related to whole brain radiotherapy in breast cancer patients with brain metastases. And explore the clinical and molecular parameter for predicting severe cognitive impairment induced by WBRT and gaining benefit from GM1. Primary Endpoint: the change of Hopkins Verbal and Learning Test-Revised Delayed Recall,HVLT-R DR,before and after WBRT Secondary ENDPOINT: the change of Alzheimer's Disease Assessment Scale-Cognitive，ADAS-Cog before and after WBRT;severe cognitive impairment percentage and onset time; Design:204 patients will be randomly assigned to exp.group,102 cases,and 102 cases of control group.

Brain MetastasesRadiotherapy Side EffectCognitive Impairment+2 more

Sun Yat-sen University51 participantsStarted May 2020

Guangzhou, Guangdong, China

GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

GM1 Prophylaxis for WBRT Related Cognitive Dysfunction

Related Searches

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

Investigation of Genetic Determinants of Capecitabine Toxicity

Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer

Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer Screening

Laser Speckle Imaging During Breast Reconstruction

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Cancer Patient Perspectives During COVID-19

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

Effect of Kefir on Symptom Management and Quality of Life in Oncology

Southeast Netherlands Advanced Metastatic Breast Cancer Registry

A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.

An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study

ctDNA Monitoring in Early Breast Cancer